Detection of active P‑glycoprotein in systemic lupus erythematosus patients with poor disease control

Zhang,Bo; Shi,Ying; Lei,Tie‑Chi

doi:10.3892/etm.2012.667

Detection of active P‑glycoprotein in systemic lupus erythematosus patients with poor disease control

Authors:
- Bo Zhang
- Ying Shi
- Tie‑Chi Lei
View Affiliations

Affiliations: Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: August 16, 2012 https://doi.org/10.3892/etm.2012.667
Pages: 705-710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Active P‑glycoprotein (P‑gp) molecules have been shown to transport steroids out of peripheral lymphocytes, resulting in poor responses to systemic steroid therapy in patients with systemic lupus erythematosus (SLE). This study was carried out to investigate the correlation between the expression or activity of P‑gp in peripheral lymphocytes and disease control in SLE patients with a long history of systemic steroid treatment. A total of 60 SLE patients who had received systemic steroid treatment for longer than 6 months and 30 healthy subjects were monitored. SLE patients were subclassified into those with active and severely active forms of the disease according to their disease activity (estimated by SLEDAI-2000). The expression levels and activity of P‑gp in peripheral blood lymphocytes were determined. Lymphocytes, obtained from three patients with severely active SLE, with high levels of P‑gp expression were treated with cyclophosphamide, mycophenolic acid or emodin in vitro and Rh123‑efflux activity was measured. P‑gp expression in the peripheral lymphocytes of the SLE patients was significantly higher compared with that of the healthy controls, and a positive correlation between disease activity and P‑gp expression levels was observed in these 60 patients. A significant increase in P‑gp expression was observed in the severely active compared with the active SLE group. Treatment of lymphocytes with 100 µM cyclophosphamide or 100 µM emodin in vitro induced up to a 2‑fold increase in the mean fluorescence intensity, as detected by the Rh123‑efflux assay. In conclusion, the high expression levels of P‑gp in the peripheral lymphocytes of SLE patients leads to poor disease control by systemic steroids. Emodin, an active ingredient derived from Chinese herbs, possesses a promising effect for overcoming P‑gp-mediated steroid resistance by inhibiting the P-gp efflux function.

View Figures

View References

1	D’Cruz DP, Khamashta MA and Hughes GR: Systemic lupus erythematosus. Lancet. 369:587–596. 2007.
2	Parker BJ and Bruce IN: High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus. 16:387–393. 2007. View Article : Google Scholar : PubMed/NCBI
3	Wallace DJ: Advances in drug therapy for systemic lupus erythematosus. BMC Med. 29:772010. View Article : Google Scholar
4	Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 120:76–85. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tsujimura S, Saito K, Nakayamada S, Nakano K and Tanaka Y: Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum. 52:1676–1683. 2005. View Article : Google Scholar : PubMed/NCBI
6	Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J and Llorente L: P-glycoprotein in autoimmune diseases. Autoimmun Rev. 3:188–192. 2004. View Article : Google Scholar
7	Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
8	Gladman DD, Ibañez D and Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 29:288–291. 2002.PubMed/NCBI
9	Yee CS, Farewell VT, Isenberg DA, et al: The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 50:982–988. 2011. View Article : Google Scholar
10	Feng X, Wu H, Grossman JM, et al: Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54:2951–2962. 2006. View Article : Google Scholar : PubMed/NCBI
11	Petri M, Kim MY, Kalunian KC, et al: Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 353:2550–2558. 2005. View Article : Google Scholar : PubMed/NCBI
12	de la Fuente H, Baranda L, Hernández MI, et al: Lack of involvement of P-glycoprotein (P-gp) in pemphigus patients with poor response to steroid therapy. J Dermatol Sci. 28:219–226. 2002.PubMed/NCBI
13	Grishanova AY, Melnikova EV, Kaledin VI, Nikolin VP and Lyakhovich VV: Possible role of P-glycoprotein in cyclophosphamide resistance of transplanted mouse RLS lymphosarcoma. Bull Exp Biol Med. 139:611–614. 2005. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Figurski M, Shaw LM and Burckart GJ: The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl Immunol. 19:192–196. 2008.(In English and Russian).
15	Li J, Liu P, Mao H, Wanga A and Zhang X: Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep. 21:1605–1610. 2009.PubMed/NCBI
16	Guiducci C, Gong M, Xu Z, Gill M, et al: TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 465:937–941. 2010. View Article : Google Scholar : PubMed/NCBI
17	Tsujimura S, Saito K, Tokunaga M, et al: Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Mod Rheumatol. 15:28–32. 2005. View Article : Google Scholar
18	Foote A, Briganti EM, Kipen Y, et al: Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 31:268–273. 2004.PubMed/NCBI
19	Hoi AY, Hickey MJ, Hall P, Yamana J, et al: Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol. 177:5687–5696. 2006. View Article : Google Scholar
20	Li X, Zhang FS, Zhang JH and Wang JY: Negative relationship between expression of glucocorticoid receptor alpha and disease activity: glucocorticoid treatment of patients with systemic lupus erythematosus. J Rheumatol. 37:316–321. 2010. View Article : Google Scholar
21	Callaghan R, Crowley E, Potter S and Kerr ID: P-glycoprotein: so many ways to turn it on. J Clin Pharmacol. 48:365–378. 2008. View Article : Google Scholar : PubMed/NCBI
22	Wasilewska A, Zoch-Zwierz W, Pietruczuk M and Zalewski G: Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr Nephrol. 21:1274–1280. 2006. View Article : Google Scholar : PubMed/NCBI
23	Barnes PJ and Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet. 373:1905–1917. 2009. View Article : Google Scholar : PubMed/NCBI
24	Farrell RJ and Kelleher D: Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 178:339–346. 2003. View Article : Google Scholar : PubMed/NCBI
25	Tsujimura S, Saito K, Nakayamada S and Tanaka Y: Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Mod Rheumatol. 20:139–146. 2010. View Article : Google Scholar : PubMed/NCBI
26	Maillefert JF, Maynadie M, Tebib JG, et al: Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol. 35:430–435. 1996. View Article : Google Scholar